SERA PROGNOSTICS, INC. 8-K

What Happened
Sera Prognostics, Inc. announced on January 7, 2026 (via an 8-K and accompanying press release) that the results of its PRIME study—Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs—were published in the Pregnancy Journal (link in filing). The company said these newly published results will be discussed during a Jefferies-hosted fireside chat on January 9, 2026 at 8:30 a.m. ET. The press release is furnished as Exhibit 99.1 to the Form 8-K.

Key Details

• Press release and Regulation FD disclosure filed on January 7, 2026.
• PRIME = Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs.
• Study results published in the Pregnancy Journal (publication link provided in the filing).
• Company to discuss results in a Jefferies fireside chat on January 9, 2026 at 8:30 a.m. ET.
• Form 8-K signed by CFO Austin Aerts.

Why It Matters
Publication of clinical study results in a peer-reviewed journal and the scheduled investor-facing presentation make the PRIME results publicly available and accessible to clinicians, investors, and partners. For investors, this increases transparency around the company’s clinical data and may affect the company’s scientific credibility and commercial conversations; the filing does not include financial results, guidance, or other operational changes.